Voclosporin doubles proteinuria reduction in lupus nephritis but raises adverse eventsVoclosporin Shows Better Results for Lupus Nephritis Protein Reduction

International urology and nephrology Published September 3, 2026 Study authors: Sayed Mohamed Saad, Murad Mohamed R, Kareem Hasan Naeem, Belabaci Zineddine, Abdelhamid Marym Taha, … PubMed ↗ DOI ↗ Editorial oversight: Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway

Consider voclosporin for LN remission but monitor for increased adverse events.

This meta-analysis of randomized controlled trials evaluated the efficacy and safety of voclosporin added to standard treatment versus placebo in 770 adult patients with lupus nephritis. The primary outcome was reduction in proteinuria, with secondary outcomes including complete and partial response. Follow-up assessments were conducted at 6 and 12 months.

Voclosporin significantly increased the rate of achieving a reduction in the urine protein-to-creatinine ratio (UPCR) below 50% of baseline (HR 1.97, 95% CI 1.66 to 2.35, log-rank p < 0.001) and below 0.5 g/g (HR 1.84, 95% CI 1.43 to 2.37, log-rank p < 0.001). These results suggest superior efficacy in inducing remission and reducing proteinuria.

However, both adverse events and serious adverse events were significantly increased in the voclosporin group. The authors note that larger primary studies are needed to explore its exact safety profile. The meta-analysis did not report funding or conflicts of interest.

Clinicians should weigh the potential for improved renal response against the increased risk of adverse effects when considering voclosporin for lupus nephritis. The evidence supports efficacy but underscores the need for careful monitoring and further safety data.

How this fits prior evidence

This meta-analysis extends prior coverage by quantifying the benefit of a targeted therapy in lupus nephritis. It aligns with the earlier finding that standard therapy fails 30% to 40% of patients, suggesting voclosporin as an additional option. It also complements the report on obinutuzumab in active SLE by showing another agent with superior response rates, though with increased adverse events. The results do not directly address the chemokine network or cGAS-STING pathways, but they reinforce the ongoing search for effective LN treatments beyond standard therapy.

Researchers analyzed data from 770 adult patients with Lupus Nephritis to see how adding voclosporin to standard treatment affected kidney health. The study looked at how well the medication reduced proteinuria, which is the presence of excess protein in the urine.

The results showed that patients who received voclosporin had a higher rate of significant protein reduction compared to those who received a placebo. Specifically, the group receiving voclosporin showed a higher reduction in the urine protein-to-creatinine ratio. These findings suggest that voclosporin may be more effective at inducing remission and lowering protein levels in the urine.

While the medication showed stronger results for managing symptoms, it also came with more risks. The study reported that patients taking voclosporin experienced a significantly higher number of adverse events and serious adverse events. Because the safety profile is not fully known, larger studies are still needed to understand the risks clearly. Patients should talk to their doctor to weigh these benefits and risks.

What this means for you:

Voclosporin may reduce urine protein in Lupus Nephritis patients but is linked to a higher risk of side effects.

Common questions

How does voclosporin help with Lupus Nephritis?

When added to standard treatment, voclosporin was shown to be more effective at reducing the amount of protein in the urine. Specifically, it showed a higher reduction in the urine protein-to-creatinine ratio compared to a placebo. This helps manage the symptoms of Lupus Nephritis in adult patients.

Is voclosporin safe for patients with Lupus Nephritis?

The study found that patients taking voclosporin experienced a significantly higher number of adverse events and serious adverse events compared to those on a placebo. Because more research is needed to fully understand its safety profile, you should discuss these risks with your doctor.

What are the main findings regarding protein reduction?

The study showed that patients receiving voclosporin had a higher reduction of the urine protein-to-creatinine ratio below 50% of their baseline value. It also showed a higher reduction for those with a ratio below 0.5 g/g compared to the placebo group.

Study Details

Study typeMeta analysis

Sample sizen = 770

EvidenceLevel 1

Follow-up6.0 mo

PublishedSep 2026

PMID41922881

View Original Abstract ↓

BACKGROUND: Lupus Nephritis (LN) is one of the most common complications of systemic lupus erythematosus. Recent primary studies have stated the superiority of adding voclosporin to standard treatment regimens in reducing proteinuria in LN patients. In this meta-analysis, we evaluate the safety and efficacy of combining voclosporin in patients with LN. METHODS: We searched PubMed, Embase, Scopus, and Web of Science on February 25, 2025, to identify randomized controlled trials (RCTs) that compared the use of voclosporin with standard treatment versus placebo. The Cochrane ROB 2.0 tool was used to assess the quality of the included studies. Cumulative hazard ratio (HR) and risk ratio (RR) with their corresponding 95% confidence intervals (CI) were calculated using R and RevMan software. RESULTS: 770 patients with LN were included in the three RCTs, with a mean age of 33.01(SD, 9.94) years. Voclosporin significantly achieved a higher reduction of the urine protein-to-creatinine ratio (UPCR) below 50% of its baseline value [HR: 1.97, 95% CI 1.66 to 2.35, log-rank p < 0.001], and below 0.5 g/g [HR: 1.84, 95% CI 1.43 to 2.37, log-rank p < 0.001] compared to placebo. There were higher complete and partial response rates at 6 months and 12 months in the voclosporin group, respectively. The overall adverse events and treatment-related serious adverse events significantly increased in the voclosporin group, which increases the clinical concerns of using voclosporin in LN patients. CONCLUSION: This analysis highlights the superior efficacy outcomes of voclosporin in inducing LN remission and reducing proteinuria. However, the risk of adverse effects was higher when voclosporin was used. Larger primary studies are needed to explore its exact safety profile.

Voclosporin doubles proteinuria reduction in lupus nephritis but raises adverse eventsVoclosporin Shows Better Results for Lupus Nephritis Protein Reduction

How this fits prior evidence

Common questions

Study Details

Evaluating the Efficacy of Traditional Chinese Medicine Decoctions for Rheumatoid Arthritis Management

Traditional Chinese medicine decoctions may improve rheumatoid arthritis symptoms

Clinical research that matters. Delivered to your inbox.

Voclosporin doubles proteinuria reduction in lupus nephritis but raises adverse eventsVoclosporin Shows Better Results for Lupus Nephritis Protein Reduction

How this fits prior evidence

Common questions

More on Systemic Lupus Erythematosus

Study Details

Evaluating the Efficacy of Traditional Chinese Medicine Decoctions for Rheumatoid Arthritis Management

Traditional Chinese medicine decoctions may improve rheumatoid arthritis symptoms

Clinical research that matters. Delivered to your inbox.

Related in Rheumatology

From Other Specialties